Dr. Wyatt’s research is focused on metastatic genitourinary cancers, including prostate and bladder cancer. To enable genomic profiling of these cancers, his team has pioneered methods for circulating tumour DNA analysis of prostate cancer from minimally invasive blood samples,  developed targeted sequencing approaches, built custom bioinformatic software and amassed important clinical data from men with metastatic prostate cancer, enabling comparison of genomic alterations with treatment outcomes.

Dr. Wyatt designed the circulating tumour DNA screening strategy and directs the molecular tumour board for the Canadian Cancer Trials Group (CCTG) Phase II precision oncology umbrella trial for metastatic prostate cancer. The Canada-wide trial matches patients with treatments based on analysis of their circulating tumour DNA and has enrolled more than 350 patients to date. His laboratory is also working to bring his research to the clinic by creating a panel-based circulating tumour DNA test that could be used as part of routine clinical practice.

Dr. Wyatt has been the recipient of multiple awards including a Coalition to Cure Prostate Cancer Young Investigator Award from the Prostate Cancer Foundation, a Movember Rising Star in Prostate Cancer Research Award from Prostate Cancer Canada and an Early Career Investigator Award from the Canadian Institutes of Health Research.

Dr. Wyatt received his PhD in human genetics from the University of Oxford and conducted his postdoctoral research at the Vancouver Prostate Centre, where in 2015, he become a Senior Research Scientist, as well as a UBC faculty member. 

Learn more about Dr. Wyatt’s research here.

  • Senior Research Scientist, Vancouver Prostate Centre
  • Assistant Professor, Department of Urologic Sciences, University of British Columbia
  • BSc., Biology, University of Nottingham, UK
  • PhD, Human Genetics, University of Oxford, UK
Back to top